Translational Oncology involves moving scientific discoveries made in a laboratory setting into clinical applications that enhance treatment efficacy and outcomes for cancer patients. Translational Oncology approaches include pre-clinical research, which can be done in an in vivo, in vitro, or ex vivo setting, before validating the laboratory findings with a clinical trial.
Consistent accuracy in reporting quantitative viral load results is critically important to patients, their physicians and to the clinical laboratory. In clinical practice, quantitative viral...
Matching the mutational profile of a patient's tumor with appropriate targeted agents is a goal of personalized medicine in oncology. The number of FDA-approved targeted therapies, as well as...
DATE: Tuesday, May 26th, 2015TIME: 09:00AM PDT, 12:00PM EDTNext-generation sequencing (NGS) is changing the landscape of clinical research. This powerful technology is enabling researchers to...
DATE: Tuesday, March 10, 2015 TIME: 09:00 PST, 11:00 CST, 12:00 EST, 16:00 GMTThe International Myeloma Working Group (IMWG) has issued updated criteria for the diagnosis of multiple...
The field of surgical research has been growing rapidly with the development of new surgical and disease models. An extremely important and often overlooked aspect of creating these models is...
Although the incidence of breast cancer is steadily increasing, mortality rates are decreasing. This means that the majority of women with breast cancer now survive, making it even more impor...
Over the last decade we have witnessed tremendous advances in our understanding of the underlying molecular alterations in human cancer. This has stimulated excitement for our ability to deve...
Survival rates for early stage non-small cell lung cancer (NSCLC) remain unacceptably low compared to other common solid tumors. This mortality reflects a weakness in conventional staging, as...
Illumina next-generation sequencing (NGS) and microarray technologies are revolutionizing cancer research, enabling cancer variant discovery and detection and molecular monitoring. Join u...
Patient-derived xenograft (PDX) models can recapitulate patient tumor histopathology, mutational status, gene expression patterns, and drug response with remarkable fidelity. At The Jackson L...
The effective implementation of personalised cancer therapeutic regimens depends on the successful identification and translation of informative biomarkers to aid clinical decision-making. An...
Master regulatory transcription factors localize to the genome in a manner influenced by chromatin accessibility and influencing global chromatin structure. With an interest in understanding...
This presentation will focus on NuMediis general approach towards the discovery of new therapeutic uses for existing drugs. While the business models for repurposing marketed drugs versus rep...
Patients with chromosomal rearrangements resulting in fusion proteins are among the most responsive to published targeted therapy. For example, targeting of the EML4-ALK fusion in non-small c...
Late-stage drug attrition rates in oncology remain higher than in other therapeutic areas. To reduce attrition, it is critical to identify appropriate drug targets and pre-clinical models. Th...
The use of biomarkers for the stratification of populations for therapy is a concept that holds the potential to revolutionize clinical trial design, the economics of healthcare, and most imp...
In this webinar, we will describe a comprehensive approach for NGS-based marker discovery and the successful migration of these markers to targeted NGS assays using low-quality (FFPE) and low...
One of the major challenges to oncology based drug discovery and development has been the limited or incremental impact that many targeted agents have exhibited in the clinic. Understanding a...
While the "Jolie effect" has refocused attention on the central role of BRCA gene analyses in the diagnosis and prevention of hereditary breast and ovarian cancer, there is a global disparity...
Genome sequencing technologies have enabled a rapid expansion into understanding cancer biology, drug development, and treatment resistance. Research in our laboratory has focused on the app...
The proper surgical techniques represent a key opportunity to improve the welfare of laboratory rodents, while meeting legal and ethical obligations. Use of inappropriate or poor surgical tec...
With the growth and expansion of mouse and rat transgenic models in recent years, the demand for surgically altered models mimicking human diseases is growing at an amazing rate. Surgical pro...
Invading cancer cells leave the tumor to form distant metastases and are ultimately responsible for 90% of deaths in cancer. Reducing the ability of cancer cells to invade and metastasize cou...
Consistent accuracy in reporting quantitative viral load results is critically important to patients, their physicians and to the clinical laboratory. In clinical practice, quantitative viral...
Matching the mutational profile of a patient's tumor with appropriate targeted agents is a goal of personalized medicine in oncology. The number of FDA-approved targeted therapies, as well as...
DATE: Tuesday, May 26th, 2015TIME: 09:00AM PDT, 12:00PM EDTNext-generation sequencing (NGS) is changing the landscape of clinical research. This powerful technology is enabling researchers to...
DATE: Tuesday, March 10, 2015 TIME: 09:00 PST, 11:00 CST, 12:00 EST, 16:00 GMTThe International Myeloma Working Group (IMWG) has issued updated criteria for the diagnosis of multiple...
The field of surgical research has been growing rapidly with the development of new surgical and disease models. An extremely important and often overlooked aspect of creating these models is...
Although the incidence of breast cancer is steadily increasing, mortality rates are decreasing. This means that the majority of women with breast cancer now survive, making it even more impor...
Over the last decade we have witnessed tremendous advances in our understanding of the underlying molecular alterations in human cancer. This has stimulated excitement for our ability to deve...
Survival rates for early stage non-small cell lung cancer (NSCLC) remain unacceptably low compared to other common solid tumors. This mortality reflects a weakness in conventional staging, as...
Illumina next-generation sequencing (NGS) and microarray technologies are revolutionizing cancer research, enabling cancer variant discovery and detection and molecular monitoring. Join u...
Patient-derived xenograft (PDX) models can recapitulate patient tumor histopathology, mutational status, gene expression patterns, and drug response with remarkable fidelity. At The Jackson L...
The effective implementation of personalised cancer therapeutic regimens depends on the successful identification and translation of informative biomarkers to aid clinical decision-making. An...
Master regulatory transcription factors localize to the genome in a manner influenced by chromatin accessibility and influencing global chromatin structure. With an interest in understanding...
This presentation will focus on NuMediis general approach towards the discovery of new therapeutic uses for existing drugs. While the business models for repurposing marketed drugs versus rep...
Patients with chromosomal rearrangements resulting in fusion proteins are among the most responsive to published targeted therapy. For example, targeting of the EML4-ALK fusion in non-small c...
Late-stage drug attrition rates in oncology remain higher than in other therapeutic areas. To reduce attrition, it is critical to identify appropriate drug targets and pre-clinical models. Th...
The use of biomarkers for the stratification of populations for therapy is a concept that holds the potential to revolutionize clinical trial design, the economics of healthcare, and most imp...
In this webinar, we will describe a comprehensive approach for NGS-based marker discovery and the successful migration of these markers to targeted NGS assays using low-quality (FFPE) and low...
One of the major challenges to oncology based drug discovery and development has been the limited or incremental impact that many targeted agents have exhibited in the clinic. Understanding a...
While the "Jolie effect" has refocused attention on the central role of BRCA gene analyses in the diagnosis and prevention of hereditary breast and ovarian cancer, there is a global disparity...
Genome sequencing technologies have enabled a rapid expansion into understanding cancer biology, drug development, and treatment resistance. Research in our laboratory has focused on the app...
The proper surgical techniques represent a key opportunity to improve the welfare of laboratory rodents, while meeting legal and ethical obligations. Use of inappropriate or poor surgical tec...
With the growth and expansion of mouse and rat transgenic models in recent years, the demand for surgically altered models mimicking human diseases is growing at an amazing rate. Surgical pro...
Invading cancer cells leave the tumor to form distant metastases and are ultimately responsible for 90% of deaths in cancer. Reducing the ability of cancer cells to invade and metastasize cou...
Opens in a new windowOpens an external siteOpens an external site in a new window
Follow
